Oxford BioTherapeutics makes C Glenn Begley a director
This article was originally published in Scrip
Executive Summary
Oxford BioTherapeutics, a biotech developing antibody-based cancer medicines, has appointed Dr C Glenn Begley a senior clinical advisor and non-executive director. Dr Begley, who previously served as vice-president and global head of haematology and oncology research at Amgen, will take a key role in shaping and executing OBT's clinical and corporate strategy.